Debate: Is there a standard second line therapy for HCC? - Regorafenib is a winner - 100004

Spotlight
Video

Debate: Is there a standard second line therapy for HCC? - Regorafenib is a winner

imedex has 1207 videos Subscribe Here

Loading........
Description: In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Ghassan Abou-Alfa argues that regorafenib should be the standard second line therapy for hepatocellular carcinoma (HCC).

Earn CME Credit for a related activity: http://elc.imedex.com/ELC/S...

© 2017 Imedex, LLC.
Shared By : imedex
Posted on : 08/23/17
Added : 5 months ago



Recommended

Nothing found.